Press release
Radioligand Therapy (RLT) Market worth US$10.9 billion by 2035 with 13.2% CAGR
North America accounts for the largest share of the global Radioligand Therapy (RLT) market in 2024, driven by its advanced healthcare infrastructure, high adoption of innovative oncology treatments, and strong presence of leading pharmaceutical and biote
The global Radioligand Therapy (RLT) Market [https://www.marketsandmarkets.com/Market-Reports/radioligand-therapy-rlt-market-238791830.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=radioligandtherapy(RLT)market], valued at US$2.36 billion in 2024, stood at US$3.15 billion in 2025 and is projected to advance at a resilient CAGR of 13.2% from 2025 to 2035, culminating in a forecasted valuation of US$10.91 billion by the end of the period. The growth of this market is primarily attributed to factors such as increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, and the rising adoption of PSMA and SSTR PET imaging for patient selection. However, the isotope scarcity for Lu-177 and Ac-225, which creates supply bottlenecks, is predicted to cause market growth barriers.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=238791830 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=238791830&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=radioligandtherapy(RLT)market]
By indication, the market is segmented into prostate cancer, neuroendocrine tumours (NETS), and other indications. In 2024, the prostate cancer segment accounted for the largest share of the market. This indication has a robust clinical need and rapid adoption of novel targeted therapies. Prostate cancer remains one of the most prevalent malignancies among men worldwide, with a particularly high burden of advanced and metastatic castration-resistant prostate cancer (mCRPC). Radioligand therapies such as Lutetium-177 vipivotide tetraxetan (Pluvicto) and emerging PSMA-targeted radiopharmaceuticals like [Lu-177]-PNT2002 and 177Lu-PSMA-I&T have demonstrated significant improvements in patient outcomes, including prolonged survival and better quality of life in late-stage patients who have exhausted conventional treatment options.
By end user, the market is segmented into the tertiary care academic/ comprehensive cancer centers segment had the largest market share in 2024. These institutions are equipped with advanced diagnostic & therapeutic technologies, enabling the integration of precision medicine approaches such as radioligand therapy into routine clinical practice. Their multidisciplinary teams, comprising oncologists, nuclear medicine specialists, and researchers, drive the adoption of innovative treatments for conditions like prostate cancer and neuroendocrine tumors. Academic and comprehensive centers also serve as hubs for clinical trials, accelerating the translation of promising RLT candidates from research to real-world application. With strong collaborations with pharmaceutical companies and biotech innovators, they play a crucial role in generating clinical evidence and setting treatment standards globally.
By geography, North America accounts for the largest share of the global Radioligand Therapy (RLT) market in 2024, driven by its advanced healthcare infrastructure, high adoption of innovative oncology treatments, and strong presence of leading pharmaceutical and biotechnology companies. The region benefits from early approvals of key radioligand therapies, including Lutetium-177-based products, and a well-established regulatory framework that facilitates rapid clinical development and commercialization. The rising incidence of prostate cancer and neuroendocrine tumors, coupled with growing awareness of targeted therapies, has significantly fueled demand. Moreover, North America hosts numerous tertiary care academic and comprehensive cancer centers, hubs for clinical trials, treatment innovations, and patient access to cutting-edge RLT options. Strong investment flows, government support for nuclear medicine research, and strategic collaborations between global pharma players and local institutions further strengthen the market.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=238791830 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=238791830&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=radioligandtherapy(RLT)market]
The key players in the radioligand therapy market include Novartis (Switzerland), Bayer (Algeta) (Germany), Curium Pharma (France), Eli Lilly & Co. (Point Biopharma) (US), AstraZeneca (Fusion Pharmaceuticals Inc.) (UK), Progenics (Lantheus) (US), Ariceum Therapeutics (Germany), Telix Pharmaceuticals (Australia), ITM Isotope Technologies Munich SE (Germany), Convergent Therapeutics Inc. (US), Orano SA (France), Actinium Pharmaceuticals Inc. (US), Perspective Therapeutics (US), Clarity Pharmaceuticals (Australia), and Radiopharm Theranostics Ltd (Australia), among others.
Novartis (Switzerland):
Novartis (Switzerland) is a global pharmaceutical leader and one of the pioneers in advancing radioligand therapy (RLT). The company has played a pivotal role in shaping this therapeutic area by developing innovative targeted radioligand therapies that combine precision medicine with nuclear medicine to treat cancers. Novartis' flagship products include Lutathera (lutetium Lu 177 dotatate), approved for gastroenteropancreatic neuroendocrine tumors, and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), approved for metastatic castration-resistant prostate cancer (mCRPC). These therapies mark significant milestones in the treatment of hard-to-treat tumors and highlight Novartis' expertise in theranostics, wherein diagnostic imaging guides therapy selection.
Bayer (Germany)
Bayer has established a strong presence in the radioligand therapy (RLT) market by acquiring Algeta in 2014. This acquisition gave Bayer complete control of Xofigo (radium-223 dichloride), the first alpha-emitting radiopharmaceutical approved for treating castration-resistant prostate cancer (CRPC) with symptomatic bone metastases. Xofigo represented a groundbreaking advancement in nuclear medicine by offering targeted alpha therapy (TAT), which delivers highly localized radiation to bone metastases while minimizing damage to surrounding tissues. Bayer continues to build on this foundation by advancing research collaborations and expanding its radiopharmaceutical pipeline to address additional cancers. With its oncology and nuclear medicine expertise, Bayer remains a key innovator in the RLT field, working on both monotherapy & combination approaches to enhance clinical outcomes.
For more information, Inquire Now! [https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=238791830&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=radioligandtherapy(RLT)market]
Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=radioligand-therapy-rlt-market-worth-us109-billion-by-2035-with-132-cagr]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/radioligand-therapy-rlt-market-238791830.html
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Radioligand Therapy (RLT) Market worth US$10.9 billion by 2035 with 13.2% CAGR here
News-ID: 4210327 • Views: …
More Releases from ABNewswire
DermaStation Skin Clinic strengthens its hair loss treatment offering
The Delhi-based skin clinic offers the most advanced hair loss treatment that ensures healthier hair regrowth and improved density.
In view of the growing concerns over progressive hair fall and pattern baldness, DermaStation, a popular dermatology clinic in Delhi, enhances its Platelet Rich Plasma Therapy for better and lasting results.
The move to offer advanced platelet rich plasma treatment [https://www.dermastation.com/blog/platelet-rich-plasma-treatment-in-delhi-a-complete-guide-to-prp-therapy/] and comprehensive treatment is in line with DermaStation's commitment to provide finest…
Grand Prairie-Based Cannon System Design Addresses Rising IT Networking Demands …
Cannon System Design, a Grand Prairie technology firm established in 2019, provides IT infrastructure and security solutions across the DFW region, serving schools, hospitals, churches, and businesses with local expertise.
As businesses and institutions across the Dallas-Fort Worth area face increasing technological demands, Cannon System Design [https://www.cannonsystem.design/] has positioned itself as a reliable provider of comprehensive technology solutions. Since launching operations in 2019, the Grand Prairie-based company has been serving schools,…
CLAIMED BY GOD DESIGNS Announces 2026 Expansion Following Breakthrough Holiday P …
After achieving record holiday sales, CLAIMED BY GOD DESIGNS prepares major 2026 expansion plans to meet growing demand for faith-based fashion that empowers believers worldwide. The brand's scripture-rooted designs and innovative approach to Christian lifestyle retail continue attracting new generations of faithful consumers seeking authentic, stylish expressions of belief.
CLAIMED BY GOD DESIGNS is leveraging extraordinary holiday season success to launch ambitious expansion plans for 2026, positioning the brand to meet…
Burbank Chimney Services Advises Homeowners on Year-Round Chimney Safety
Burbank Chimney Services is advising homeowners to take a proactive approach to chimney safety during the winter heating season, when increased fireplace use can reveal underlying issues within chimney and ventilation systems. Industry professionals say colder temperatures and heavier usage often make debris accumulation, moisture intrusion, and airflow problems more noticeable and potentially hazardous.
Homeowners scheduling a Chimney Sweep [https://burbankchimneyservices.com/] are encouraged to arrange inspections during winter months, when creosote buildup,…
More Releases for RLT
Radioligand Therapy Rlt Market Emerging Trends and Growth Prospects 2034 |Novart …
"The Global Radioligand Therapy Rlt Market Size is projected to reach at a CAGR of 10.5% during 2025-2034."
Global Radioligand Therapy Rlt market Size, Status, and Forecast for the 2025-2034. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the Radioligand Therapy Rlt Market including drivers, restraints, historical and current trends, regulatory scenarios, and technological…
Radioligand Therapy (RLT) Market 2023-2030 Key Futuristic Top Trends and Competi …
Worldwide Market Reports introducing our highly anticipated "Radioligand Therapy (RLT) Market" research report 'Navigating the Future: Uncovering Market Insights for Success.' This comprehensive report is an indispensable resource for businesses seeking to thrive in today's dynamic and competitive landscape. With a wealth of meticulously gathered data, expert analysis, and actionable recommendations, this Radioligand Therapy (RLT) market report offers a deep dive into market trends, consumer behavior, and emerging opportunities across…
Rising Demand for Radioligand Therapy (RLT) Market: Latest Innovation & Upcoming …
The global 𝗥𝗮𝗱𝗶𝗼𝗹𝗶𝗴𝗮𝗻𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 (𝗥𝗟𝗧) market is estimated to attain a valuation of by the end of 2027, states a study by Transparency Market Research (TMR).
The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of the Radioligand Therapy (RLT) industry. The current and historical status of the market together with forecasted market size and trends are demonstrated…
Radioligand Therapy (RLT) Market Size, Prominent Players and Key Figures Reviewe …
The report extensively examines the global Radioligand Therapy (RLT) market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Radioligand Therapy (RLT) . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the…
New Complete Analytical Report on Radioligand Therapy Rlt Market 2023 is Thrivin …
"Worldwide Market Reports Offering with upto 70% Discount on Premium Radioligand Therapy Rlt Market Report On Purchases With Single User Access and Unlimited User Access"
Radioligand Therapy Rlt Market Research Report Forecast 2023-2030 has been prepared by experienced and knowledgeable market analysts and researchers. Each section of the research study is specially prepared to explore key aspects of the Industry. Buyers of the report will have access to accurate Porter's…
Radioligand Therapy (RLT) Market Size And Forecast - Telix Pharmaceuticals, Lant …
Newark, New Castle, USA Radioligand Therapy (RLT) Market Analysis 2022 | by Drug Class (Anti-androgen, Therapeutic Radiopharmaceuticals), Indication (Prostate Cancer, Neuroendocrine Tumors) Business Opportunities, Pricing Strategy, Forthcoming opportunities planning, Market-specific challenges, Globally Market Key Facts are coverd in this report by Growth Plus Reports | 100+ Report Pages
Radioligand Therapy (RLT) Market 2022 with 100+ Pages Report and enhance with extents shares into sub-counties are covered in this market. Radioligand Therapy…
